The dosage of enzalutamide employed in our ex vivo model of human prostate cancer PDE model is 10 μM (4.6 μg/ml) and importantly, this is comparable to plasma concentrations readily achieved systemically in clinical patients38. This evidence concerns the gene ALDH7A1 and Familial prostate cancer.